Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
[ Wed, Feb 08th 2012 ]: Market Wire
Imaging3 Updates Website
Tue, February 7, 2012
Mon, February 6, 2012
Sun, February 5, 2012
[ Sun, Feb 05th 2012 ]: Market Wire
30 a.m. ET
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012
Wed, February 1, 2012
Tue, January 31, 2012
[ Tue, Jan 31st 2012 ]: Market Wire
00 AM EST
Mon, January 30, 2012

CORRECTING and REPLACING Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. nt-at-bio-ceo-conference-february-13th-2012.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

CAMBRIDGE, Mass.--([ ])--Headline of release should read: Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012 (sted Idera Pharmaceuticals to Present at BIO CEO Conference February 14th, 2012)

The corrected release reads:

IDERA PHARMACEUTICALS TO PRESENT AT BIO CEO CONFERENCE FEBRUARY 13TH, 2012

Idera Pharmaceuticals (Nasdaq: IDRA) today announced that Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference on February 13th at 10:30 am ET. Dr. Agrawal will provide a review of Idera's Toll-like Receptor-targeted development programs in oncology and autoimmune diseases as well as its gene silencing oligonucleotide (GSO) technology.

The live webcast of the presentation will be available in the Investor section of Idera's website: [ www.iderapharma.com ]. An archived version will also be available on the Company's website after the event for a limited time. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The Company's TLR-targeted candidates are being developed to treat autoimmune and inflammatory diseases and cancer, and for use as vaccine adjuvants. Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit[ http://www.iderapharma.com ].


Publication Contributing Sources